Since in 2014, when the FDA approved pembrolizumab, the first PD-L1/PD-1 pathway inhibitor, for the treatment of advanced unresectable melanoma [15], multiple clinical trials have indicated that PD-L1/PD-1 pathway inhibitors can induce a potent and durable immune response against cancer cells [16–19]. Here, PDCD1 is linked to cancer.